학술논문
Impact of prior chemotherapy on outcomes with trabectedin/pegylated liposomal doxorubicin in recurrent ovarian cancer.
Document Type
Article
Author
Source
Subject
*TRABECTEDIN
*OVARIAN cancer
*DOXORUBICIN
*CANCER chemotherapy
*PROGRESSION-free survival
*
*
*
*
Language
ISSN
1885-740X
Abstract
Aim: The aim of this study was to evaluate the effect of number of prior chemotherapy lines, and the possible impact of poly (ADP-ribose) polymerase inhibitor (PARPi) pre-treatment, on the efficacy of trabectedin/pegylated liposomal doxorubicin (PLD) in women with platinum-sensitive recurrent ovarian cancer (ROC). Patients and methods: A post hoc analysis of the pan-European NIMES-ROC study was performed. Women with platinumsensitive ROC who received ≥ 1 cycle of trabectedin/PLD (n = 218) were enrolled from routine clinical practice. Results: No differences in progression-free survival, overall survival, or safety profile were seen between patients pretreated with ≥ 2 prior platinum-based lines versus recipients of < 2 lines of prior chemotherapy. Among seven patients pretreated with PARPi, trabectedin/PLD provided some clinical benefit. Conclusion: Trabectedin/PLD activity was retained in ROC patients pretreated with ≥ 2 prior platinum-based lines. [ABSTRACT FROM AUTHOR]